Skip NavigationSkip to Content
Return Return to Search Results

A Novel Nanoparticulate Formulation of Arsenic Trioxide with Enhanced Therapeutic Efficacy in a Murine Model of Breast Cancer

  1. Author:
    Ahn, R. W.
    Chen, F.
    Chen, H. M.
    Stern, S. T.
    Clogston, J. D.
    Patri, A. K.
    Raja, M. R.
    Swindell, E. P.
    Parimi, V.
    Cryns, V. L.
    O'Halloran, T. V.

  2. Author Address

    [O'Halloran, Thomas V.] Northwestern Univ, Dept Chem, Chem Life Proc Inst, Evanston, IL 60208 USA. [Chen, Feng; Cryns, Vincent L.] Northwestern Univ, Dept Med, Cell Death Regulat Lab, Chicago, IL 60611 USA. [Chen, Feng; Cryns, Vincent L.] Northwestern Univ, Dept Cell & Mol Biol, Cell Death Regulat Lab, Evanston, IL 60208 USA. [Parimi, Vamsi] Northwestern Univ, Pathol Core Facil, Feinberg Sch Med, Evanston, IL 60208 USA. [Ahn, Richard W.; Chen, Feng; Chen, Haimei; Raja, Meera R.; Swindell, Elden P.; Parimi, Vamsi; Cryns, Vincent L.; O'Halloran, Thomas V.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [Stern, Stephan T.; Clogston, Jeffrey D.; Patri, Anil K.] NCI, Nanotechnol Characterizat Lab, Adv Technol Program, SAIC Frederick Inc, Frederick, MD 21701 USA.;O'Halloran, TV, Northwestern Univ, Dept Chem, Chem Life Proc Inst, 2145 Sheridan Rd, Evanston, IL 60208 USA.;v-cryns@northwestern.edu t-ohalloran@northwestern.edu
    1. Year: 2010
    2. Date: Jul
  2. Journal: Clinical Cancer Research
    1. 16
    2. 14
    3. Pages: 3607-3617
  4. Type of Article: Article
  5. ISSN: 1078-0432
  1. Abstract:

    Purpose: The clinical success of arsenic trioxide (As2O3) in hematologic malignancies has not been replicated in solid tumors due to poor pharmacokinetics and dose-limiting toxicity. We have developed a novel nanoparticulate formulation of As2O3 encapsulated in liposomal vesicles or "nanobins" [(NB(Ni, As)] to overcome these hurdles. We postulated that nanobin encapsulation of As2O3 would improve its therapeutic index against clinically aggressive solid tumors, such as triple-negative breast carcinomas. Experimental Design: The cytotoxicity of NB(Ni, As), the empty nanobin, and free As2O3 was evaluated against a panel of human breast cancer cell lines. The plasma pharmacokinetics of NB(Ni, As) and free As2O3 were compared in rats to measure drug exposure. In addition, the antitumor activity of these agents was evaluated in an orthotopic model of human triple-negative breast cancer. Results: The NB(Ni, As) agent was much less cytotoxic in vitro than free As2O3 against a panel of human breast cancer cell lines. In contrast, NB(Ni, As) dramatically potentiated the therapeutic efficacy of As2O3 in vivo in an orthotopic model of triple-negative breast cancer. Reduced plasma clearance, enhanced tumor uptake, and induction of tumor cell apoptosis were observed for NB(Ni, As). Conclusions: Nanobin encapsulation of As2O3 improves the pharmacokinetics and antitumor efficacy of this cytotoxic agent in vivo. Our findings demonstrate the therapeutic potential of this nanoscale agent and provide a foundation for future clinical studies in breast cancer and other solid tumors. Clin Cancer Res; 16(14); 3607-17. (C) 2010 AACR.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1158/1078-0432.ccr-10-0068
  3. View record in Web of Science®
  4. WOS: 000279903100010

Library Notes

  1. Fiscal Year: FY2009-2010
NCI at FrederickClose Button

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel